Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base
Posted inClinical Updates Gastroenterology Internal Medicine news

Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base

A major 2026 cluster randomized trial shows that palliative care delivered by trained hepatologists is noninferior to specialist palliative care for improving quality of life in end-stage liver disease, supporting scalable integrated models for cirrhosis and hepatocellular carcinoma.
Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit
Posted inGastroenterology Infectious Diseases news

Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit

A 2025 bayesian meta-analysis of 14 RCTs (n=1,322) found shorter or no antibiotic prophylaxis after upper GI bleeding in cirrhosis was highly likely to be noninferior for mortality, though it increased reported bacterial infections. Study limitations temper definitive practice change.
Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications
Posted inGastroenterology Internal Medicine news

Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications

Non-acute decompensation of cirrhosis (NAD) represents a distinct clinical state characterized by elevated cell death markers and moderate prognosis. Identifying predictors such as ascites severity and biomarkers Gasdermin-D and RIPK3 may guide timely interventions to prevent progression to acute decompensation and reduce mortality.